PHARMACOLOGICAL ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION

D.A. Sychev

Abstract

The author discusses the choice of dosing of new oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban), practical aspects of the application, dose adjustment, personalized choice of anticoagulants. Dosing of new oral anticoagulants depends on the pharmacokinetics and duration of action of the anticoagulant, the presence of association between the equilibrium plasma drug concentration and parameters of efficacy (thrombotic complications) and safety (bleeding). The use of the new oral anticoagulants once daily can improve compliance and safety of treatment. The results of NOAC studies in clinical practice demonstrate a high level of compliance with a single dosing regimen.

References

1. Ксарелто. Инструкция по применению. URL: http://grls.rosminzdrav.ru/.
2. Прадакса. Инструкция по применению. URL: http://grls.rosminzdrav.ru/.
4. Эликвис. Инструкция по применению. URL: http://grls.rosminzdrav.ru/.


41. Savaysa. Full prescribing information. URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf


44. Weitz J.I., Connolly S.J., Patel I. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral Factor 

45. Werth S., Koehler C., Gelbricht V. et al. Real Life Efficacy and Safety of Rivaroxaban for Stroke Prevention in Atrial Fibrillation – First Results of the Prospective Noac Registry (NCT01588119)